Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer.
Kei MizunoTakayuki SumiyoshiTakatsugu OkegawaNaoki TeradaSatoshi IshitoyaYu MiyazakiTakahiro KojimaHiromichi KatayamaNaohiro FujimotoShingo HatakeyamaMasaki ShiotaKoji YoshimuraYoshiyuki MatsuiShintaro NaritaHiroaki MatsumotoRyoma KurahashiHidenori KannoKatsuhiro ItoHiroko KimuraYuki KamiyamaTakuro SunadaTakayuki GotoTakashi KobayashiHitoshi YamadaNorihiko TsuchiyaTomomi KambaHideyasu MatsuyamaTomonori HabuchiMasatoshi EtoChikara OhyamaAkihiro ItoHiroyuki NishiyamaHiroshi OkunoToshiyuki KamotoAkihiro FujimotoOsamu OgawaShusuke AkamatsuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Detecting low-frequency ctDNA variants with a VAF <1% is important to identify clinically informative genomic alterations in CRPC.